PhD – University of Toronto, Canada (1999)
Dr. Jianrong (John) Wu's research centers on the statistical design and data analysis for Therapeutics of Solid Tumor Program (TSTP) and Pediatric Pre-Clinical Testing Program at St Jude.
My primary research interest is to develop new methodology for designing clinical trial and pre-clinical study. Pediatric cancer clinical trial is often conducted as a single-arm phase II trial or a randomized phase III trial with time-to-event endpoint, particular with a proportion of patients cured. Statistical methodology for such trial design is relatively scarce. My research is to provide more flexible and powerful statistical design for such trials. For pediatric pre-clinical tumor xenograft model, my research interest is to develop new methodology to assess the anti-tumor activity of the treatment for single drug testing and to assess the synergism for drug-drug combination testing. My other methodology research interests are survival data analysis, randomized phase III survival trial design and group sequential trial design and likelihood-based small sample and large sample inference.
Wu J. Single-arm phase II cancer survival trial designs, Journal of Biopharmaceutical Statistics 2015. DOI: 10.1080/10543406.2015.1052494
Wu J. Sample size calculation for the proportional hazards cure model [letter to the editor]. Statistics in Medicine 2015 (in press).
Wu J. Single-arm phase II trial designs under parametric cure models. Pharmaceutical Statistics 14(3):226-232, 2015.
Wu J. Power and sample size for randomized phase III survival trials under the Weibull model. Journal of Biopharmaceutical Statistics 25(1):16-28, 2015.
Wu J. Sample size calculation for the one-sample log-rank test. Pharmaceutical Statistics 14(1):26-33, 2015.
Wu J, Xiong X. Group sequential design for randomized phase III trials under the Weibull model. Journal of Biopharmaceutical Statistics Oct 16, 2014. Epub ahead of print. doi: 10.1080/10543406.2014.971165.
Wu J, Xiong X. Single-arm phase II group sequential trial design with survival endpoint at a fixed time point. Statistics in Biopharmaceutical Research 6(4):289-301, 2014.
Wu J. Power and sample size for randomized phase III survival trials under the Weibull model. Journal of Biopharmaceutical Statistics 25(1), 2015.
Xia C, Wu J, Liang H. Model tumor pattern and compare treatment effects using semiparametric linear mixed-effect models. Journal of Biometrics and Biostatistics 4:2013. doi:10.4172/2155-6180.1000168b.
Wu J. An interaction index for drug-drug combination in subcutaneous tumor xenograft studies.Pharmaceutical Statistics 12:112-119, 2013.
Navid F, Baker S, Beth M, Clinton S, Billups C, Wu J, Davidoff A, Spunt S, Furman W, Hu S, Panetta C, Turner D, Reddick G, Leung W, Santana V, Fofana D, McGregor L. Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors. Clinical Cancer Research 19(1):236-246, 2013.
Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA June;307(24):2609-2616, 2012.
Kaddoum RN, Anghelescu DL, Parish ME, Wright BB, Trujillo L, Wu J, Wu Y, Burgoyne LL, A randomized controlled trial comparing the AccuVein AV300 device to standard insertion technique for intravenous cannulation of anesthetized children. Pediatric Anesthesia June;22(9):884-889, 2012.
Cheung NK, Zhang JH, Lu C, Parker M, Bahrami, A, Tickoo SK, Heguy A, Pappo, AS, Federico S, Dalton J, Cheung IY, Ding L, Fulton B, Wang J, Chen X, Becksfort J, Wu J, Billups CA, Ellison D, Mardis ER, Wilson RK, Downing JR, Dyer MA. Association of Age at Diagnosis and Genetic Mutations in Patients with Neuroblastoma. JAMA Feb;307(10):1062-1071, 2012.
Wu J, Tracey L, Davidoff AM. Assessing interactions for fixed-dose drug combinations in tumor xenograft studies. Journal of Biopharmaceutical Statistics 22(3):535-43, 2012.
Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, Merchant TE, Haik BG, Wilson MW, Rodriguez-Galindo C. Carboplatin-Associated Ototoxicity in Children with Retinoblastoma. JCO 30(10):1034-1041, 2011.
Wu J. Confidence intervals for the difference of median failure times applied to censored tumor growth delay data. Statistics in Biopharmaceutical Research 3:488-496, 2011.
Wu J. Assessment of antitumor activity for tumor xenograft studies using exponential growth models.Journal of Biopharmaceutical Statistics 21:472-483, May, 2011.
Daw NC, Michael DN, Rao BN, MD, Billups CA, Wu J, Jenkins JJ, Quintana J, Luchtman-Jones L, Villarroel M, Santana VM. Frontline Treatment of Localized Osteosarcoma Without Methotrexate: Results of the St. Jude Children's Research Hospital OS99 Trial. Cancer 117(12):2770-2778, 2011.
Cheng C, Wu J. Interval estimation of quantile ratios applied to anti-cancer drug screening by xenograft experiments. Statistics in Medicine 29:2669-2678, Nov 20, 2010.
Wu J, Houghton PJ. Interval approach to assessing antitumor activity for tumor xenograft studies.Pharmaceutical Statistic 9:46-54, Jan, 2010. NIHMS241365b
Wu J. Statistical Inference for Tumor Growth Inhibition T/C ratio. Journal of Biopharmaceutical Statistics 20:954-964, 2010.
Robbins JR, Krasin MJ, Panandiker ASP, Watkins A, Wu J, Santana VM, Furman WL, Davidoff AM, McGregor LM. Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience. J Pediatr Surg 45:678-686, 2010.
Bhagat SP, Bass JK, White ST, Qaddoumi I, Wilson MW, Wu J, Rodriguez-Galindo C. Monitoring carboplatin ototoxicity with distortion- product otoacoustic emissions in children with retinoblastoma.International Journal of Pediatric Otorhinolaryngology 74:1156-1163, 2010.
Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L, Smith MA. Stage 2 combination testing of rapamycin with cytotoxic agents by the pediatric testing program. Molecular Cancer Therapeutics 9(1):101-12, 2010. PMID:20053767b
Daw NC, Gregornik D, Rodman J, Marina, Wu J, Kun LE, Jenkins N, Jenkins JJ, McPherson V, Wilimas J, Jones DP. Renal function after ifosfamide, carboplatin and etoposide, nephrectomy, and radiotherapy in children with wilms tumor. European Journal of Cancer 45:99-106, 2009. PMID: 18996004b
Furman WL, Navid F, Daw NC, McCarville MB, McGregor LM, Spunt SL, Rodriguez-Galindo C, Panetta JC, Crews KR, Wu J, Gajjar AJ, Houghton PJ, Santana VM, Stewart CF. Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients with Refractory Solid Tumors. Journal of Clinical Oncology 4599-4604, 2009. PMID: 19687340b
Wu J, Houghton PJ. Assessing cytotoxic treatment effects in preclinical tumor xenograft models.Journal of Biopharmaceutical Statistics 19:1-8, 2009. NIHMS221304b
Metzger ML, Stewart CF, Freeman B, Billups CA, Hoffer FA, Wu J, Coppes MJ, Grant R, Chintagumpala M, Mullen E, Alvarado, Daw NC, Dome JS. Anti-tumor Activity of Topotecan against Wilms Tumor: Results of a Multi-Institutional Phase II Study. JCO 25:3130-3136, 2007.
Rodríguez-Galindo C, Liu T, Krasin M, Navid F, MD, Wu J, Billups CA, Daw NC, Spunt SL, Rao BN, Santana VM. Analysis of Prognostic Factors in Ewing Sarcoma Family of Tumors: Review of St. Jude Children’s Research Hospital Studies. Cancer 110:375-384, 2007.
Fouladi M, Laningham F, Wu J, O’Shaughnessy M, Molina K, Broniscer A, Spunt SL, Jenkins JJ, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL. Phase I Study of Everolimus (RAD001) in Pediatric Patients with Refractory Solid Tumors. JCO 25:4806-4812, 2007.
Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Reynolds CP, Maris J, Wu J, Liu T, Billups CA, Khan J, Kier ST, Friedman HS, Smith M. The Pediatric Preclinical Testing Program: Description of Models and Early Testing Results. Pediatric Blood and Cancer, 49:928-940, 2007.
Furman WL, Crews KR, Billups CA, Wu J, Gajjar AJ, Daw NC, Patrick C, Rodriguez-Galindo C, Stewart CF, Dome JS, Panetta JC, Houghton PJ, Santana VM. Cefixime Allows Greater Dose-Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients with Refractory Solid Tumors. Journal of Clinical Oncology 24:563-570, 2006.
Wu J, Jiang GY, Wei W. Confidence interval of effect size in randomized comparative parallel-group study. Statistics in Medicine 25:639-651, 2006.
Prentice RL, Zoe M, Wu J. Hazard-based nonparametric survivor function estimation and Van der Laan’s repaired NPMLE. Journal of Royal Statistical Society, Series B 66:305-319, 2004.
Wu J, Wong ACM, Jiang GY. Likelihood-based confidence interval for log-normal mean. Statistics in Medicine 22:1849-1860, 2003.
Last update: December 2015